Tagged with research

Thailand PharmaBoardroom’s latest report: Healthcare & Life Sciences Review: Thailand is available for download now.   Thailand is in the midst of an economic transformation with healthcare at its heart. With four years of around three-four percent annual GDP growth behind it, ASEAN’s second-largest economy has implemented an ‘Industry 4.0’ policy through which…

Hungary Dr. József Mandl, President of the Medical Research Council (ETT), discusses the role of the council, the research environment in Hungary, its relationship with the European Clinical Research Infrastructure Network (ECRIN), and the strategic objectives of the research council.    Today’s partnerships, framework, committees, and bioethical codex could not exist…

Sweden With almost three decades of experience in the Swedish life science industry, Jan Hellqvist, general manager of KLIFO in Sweden, explains why the country has seen the number of clinical studies from small and medium size companies skyrocket in recent years. Moreover, he discusses the possibilities of opening KLIFO’s affiliate…

Sweden TFS is a leading mid-size CRO providing clinical development solutions to biopharmaceutical companies. Headquartered in Lund, TFS serves global clinical trial markets with local expertise and worldwide project delivery. János Filakovský, MD, Ph.d. MBA, CEO of TFS, discusses the company’s unique capabilities and analyzes the Swedish life sciences industry’s potential…

Hungary Dr Beata Sperlagh, Deputy Director of the Institute of Experimental Medicine (IEM), shares her insights on the institute’s involvement in research and with the private sector, the key strengths of IEM in the field of neuroscience, and its importance in the region.   The significant economic burden associated with brain…

UAE Dr Omar Hallak, head of the cardiovascular department at King’s College Hospital Dubai (KCHD) and president of the Gulf chapter of the International Society of Endovascular Specialists, discusses issues pertaining to cardiovascular disease (CVD) within the UAE, 4TS – a conference founded by Hallak to encourage the sharing of knowledge…

Puerto Rico Dr Amarilys Silva-Boschetti and Dr Miguel Vázquez-Padua of the Puerto Rico Consortium for Clinical Investigation (PRCCI) underline the various benefits for pharmaceutical, biotechnology and medtech companies to conduct clinical trials in Puerto Rico. They also highlight further steps of how the Consortium, which is part of the Puerto Rico Science,…

Brazil Swiss pharma giant Novartis is teaming up with the Oswaldo Cruz Foundation (Fiocruz) in Brazil to conduct research throughout Latin America on neglected diseases.   This agreement establishes an exchange of know-how that will provide progress in public health policies in Brazil Patrice Matchaba, global head of corporate responsibility, Novartis…

Czech Republic The Czech Republic is aiming to carve out a space for itself among Europe’s most innovative countries by 2030 as part of the ‘Innovation Strategy of the Czech Republic 2019–2030.’ While a number of promising steps have already been taken, it is far too soon to tell whether the Czechs…

Hungary Investments in research and development are on the rise in Hungary, backed up by government initiatives, but the country needs a more unified effort between the public and private sectors to truly deliver on its innovation potential.   On the Up Globally, R&D spending has been on a sturdy upward…

China John Moller, CEO; and Yooni Kim, executive director of Asia operations, for Novotech, share the competitive positioning of Novotech as a full-service CRO for biotech companies interested in the Asia-Pacific region; the solutions and services they offer, including their clinical development consultancy, ‘BioDesk’; as well as the exciting opportunities they…

Sweden InDex Pharmaceuticals is a Swedish biopharma company developing drugs that could help patients suffering from ulcerative colitis, an inflammatory bowel disease. CEO Peter Zerhouni gives an overview of the company’s journey, including the recent phase IIb results of their lead asset, cobitolimod, and the future strategy to bring the product…